Info

Sea Run Holdings, Inc. discovers and develops innovative biologics and therapeutics from salmon blood. Several salmon plasma proteins have been prepared for commercial use in tissue culture and diagnostics. Sea Run Holdings intends to commercialize its unique fibrin sealant as a human or veterinary hemostatic. Also, Sea Run has an extensive pipeline of products in various stages of development. Sea Run is the leading company in the world to recognize the unique properties of fish plasma and anticipate the increasing dangers of viral and prion contamination of mammalian-derived blood products. In response, the Company has developed standardized and efficient techniques for collecting large amounts of blood by aseptic methods from farmed salmon. Salmon farming is a growing industry that produces nearly 100,000 tons of fish or, potentially, 4 million liters of blood annually in the U.S. and Canada. At this time, because of a worldwide need for non-mammalian blood resources, Sea Run Holdings is exploring opportunities for the Company to greatly enhance its output by licensing its technologies and by partnering with major biomedical companies throughout the world.